Research Progress in the Clinical Treatment of Familial Hypercholesterolemia


Cite item

Full Text

Abstract

Familial hypercholesterolemia (FH) is an autosomal dominant inheritable disease with severe disorders of lipid metabolism. It is mainly marked by increasing levels of plasma total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), xanthoma, corneal arch, and early-onset coronary heart disease (CHD). The prevalence of FH is high, and it is dangerous and clinically underdiagnosed. The clinical treatment for FH includes both pharmacological and non-pharmacological treatment, of which non-pharmacological treatment mainly includes therapeutic lifestyle change and dietary therapy, LDL apheresis, liver transplantation and gene therapy. In recent years, many novel drugs have been developed to treat FH more effectively. In addition, the continuous maturity of non-pharmacological treatment techniques has also brought more hope for the treatment of FH. This paper analyzes the pathogenic mechanism and the progress in clinical treatment of FH. Furthermore, it also summarizes the mechanism and structure-activity relationship of FH therapeutic drugs that have been marketed. In a word, this article provides a reference value for the research and development of FH therapeutic drugs.

About the authors

Jing-Yan Ai

College of Pharmaceutical Science, Zhejiang University of Technology,

Email: info@benthamscience.net

Peng-Cheng Zhao

College of Pharmaceutical Science, Zhejiang University of Technology,

Email: info@benthamscience.net

Wen Zhang

College of Pharmaceutical Science, Zhejiang University of Technology,

Email: info@benthamscience.net

Guo-Wu Rao

College of Pharmaceutical Science, Zhejiang University of Technology

Author for correspondence.
Email: info@benthamscience.net

References

  1. Ose, L. Diagnostic, clinical, and therapeutic aspects of familial hypercholesterolemia in children. Semin. Vasc. Med., 2004, 4(1), 51-57. doi: 10.1055/s-2004-822986 PMID: 15199433
  2. Nohara, A.; Tada, H.; Ogura, M.; Okazaki, S.; Ono, K.; Shimano, H.; Daida, H.; Dobashi, K.; Hayashi, T.; Hori, M.; Matsuki, K.; Minamino, T.; Yokoyama, S.; Harada-Shiba, M. Homozygous familial hypercholesterolemia. J. Atheroscler. Thromb., 2021, 28(7), 665-678. doi: 10.5551/jat.RV17050 PMID: 33867421
  3. Benn, M.; Watts, G.F.; Tybjærg-Hansen, A.; Nordestgaard, B.G. Mutations causative of familial hypercholesterolaemia: Screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur. Heart J., 2016, 37(17), 1384-1394. doi: 10.1093/eurheartj/ehw028 PMID: 26908947
  4. Ma, Y.; Gong, Y.; Garg, A.; Zhou, H. Compound heterozygous familial hypercholesterolemia in a Chinese boy with a de novo and transmitted low-density lipoprotein receptor mutation. J. Clin. Lipidol., 2018, 12(1), 230-235.e6. doi: 10.1016/j.jacl.2017.10.005 PMID: 29233637
  5. Tan, K.; Cheung, C.L.; Yeung, C.Y.; Siu, D.; Leung, J.; Pang, H.K. Genetic screening for familial hypercholesterolaemia in Hong Kong. Hong Kong Med. J., 2018, 24(Suppl 3), 7-10.
  6. Stone, N.J.; Robinson, J.G.; Lichtenstein, A.H.; Bairey Merz, C.N.; Blum, C.B.; Eckel, R.H.; Goldberg, A.C.; Gordon, D.; Levy, D.; Lloyd-Jones, D.M.; McBride, P.; Schwartz, J.S.; Shero, S.T.; Smith, S.C.; Watson, K.; Wilson, P.W. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2014, 63(25 Pt B), 2889-2934. doi: 10.1016/j.jacc.2013.11.002 PMID: 24239923
  7. Nordestgaard, B.G.; Chapman, M.J.; Humphries, S.E.; Ginsberg, H.N.; Masana, L.; Descamps, O.S.; Wiklund, O.; Hegele, R.A.; Raal, F.J.; Defesche, J.C.; Wiegman, A.; Santos, R.D.; Watts, G.F.; Parhofer, K.G.; Hovingh, G.K.; Kovanen, P.T.; Boileau, C.; Averna, M.; Borén, J.; Bruckert, E.; Catapano, A.L.; Kuivenhoven, J.A.; Pajukanta, P.; Ray, K.; Stalenhoef, A.F.H.; Stroes, E.; Taskinen, M.R.; Tybjaerg-Hansen, A. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur. Heart J., 2013, 34(45), 3478-3490. doi: 10.1093/eurheartj/eht273 PMID: 23956253
  8. van der Graaf, A.; Avis, H.J.; Kusters, D.M.; Vissers, M.N.; Hutten, B.A.; Defesche, J.C.; Huijgen, R.; Fouchier, S.W.; Wijburg, F.A.; Kastelein, J.J.P.; Wiegman, A. Molecular basis of autosomal dominant hypercholesterolemia: Assessment in a large cohort of hypercholesterolemic children. Circulation, 2011, 123(11), 1167-1173. doi: 10.1161/CIRCULATIONAHA.110.979450 PMID: 21382890
  9. Bouhairie, V.E.; Goldberg, A.C. Familial Hypercholesterolemia. Cardiol. Clin., 2015, 33(2), 169-179. doi: 10.1016/j.ccl.2015.01.001 PMID: 25939291
  10. Peng, J.; Wu, X.; Wang, S.; Zhang, S.; Wang, X.; Liu, Z.; Hong, J.; Ye, P.; Lin, J. Familial hypercholesterolemia in China half a century: A review of published literature. Atheroscler. Suppl., 2019, 36, 12-18. doi: 10.1016/j.atherosclerosissup.2019.01.003 PMID: 30876527
  11. Gidding, S.S.; Ann Champagne, M.; de Ferranti, S.D.; Defesche, J.; Ito, M.K.; Knowles, J.W.; McCrindle, B.; Raal, F.; Rader, D.; Santos, R.D.; Lopes-Virella, M.; Watts, G.F.; Wierzbicki, A.S. The agenda for familial hypercholesterolemia. Circulation, 2015, 132(22), 2167-2192. doi: 10.1161/CIR.0000000000000297 PMID: 26510694
  12. Abifadel, M.; Varret, M.; Rabès, J.P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derré, A.; Villéger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J.M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N.G.; Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003, 34(2), 154-156. doi: 10.1038/ng1161 PMID: 12730697
  13. Stoekenbroek, R.M.; Kastelein, J.J.P. Proprotein convertase subtilisin/kexin type 9. Curr. Opin. Cardiol., 2018, 33(3), 269-275. doi: 10.1097/HCO.0000000000000517 PMID: 29561319
  14. Guo, Q.; Feng, X.; Zhou, Y. PCSK9 variants in familial hypercholesterolemia: A comprehensive synopsis. Front. Genet., 2020, 11, 1020. doi: 10.3389/fgene.2020.01020 PMID: 33173529
  15. Shaik, N.A.; Al-Qahtani, F.; Nasser, K.; Jamil, K.; Alrayes, N.M.; Elango, R.; Awan, Z.A.; Banaganapalli, B. Molecular insights into the coding region mutations of low density lipoprotein receptor adaptor protein 1 (LDLRAP1) linked to familial hypercholesterolemia. J. Gene Med., 2020, 22(6), e3176. doi: 10.1002/jgm.3176 PMID: 32073192
  16. Khalil, Y.A.; Rabès, J.P.; Boileau, C.; Varret, M. APOE gene variants in primary dyslipidemia. Atherosclerosis, 2021, 328, 11-22. doi: 10.1016/j.atherosclerosis.2021.05.007 PMID: 34058468
  17. Yang, S.; Ke, X.; Liang, H.; Li, R.; Zhu, H. Case report: A clinical and genetic analysis of childhood growth hormone deficiency with familial hypercholesterolemia. Front. Endocrinol., 2021, 12, 691490. doi: 10.3389/fendo.2021.691490 PMID: 34220717
  18. Parini, P.; Angelin, B.; Lobie, P.E.; Norstedt, G.; Rudling, M. Growth hormone specifically stimulates the expression of low density lipoprotein receptors in human hepatoma cells. Endocrinology, 1995, 136(9), 3767-3773. doi: 10.1210/endo.136.9.7649083 PMID: 7649083
  19. Harris, T.R.; Hammock, B.D. Soluble epoxide hydrolase: Gene structure, expression and deletion. Gene, 2013, 526(2), 61-74. doi: 10.1016/j.gene.2013.05.008 PMID: 23701967
  20. El-Sherbeni, A.A.; El-Kadi, A.O.S. The role of epoxide hydrolases in health and disease. Arch. Toxicol., 2014, 88(11), 2013-2032. doi: 10.1007/s00204-014-1371-y PMID: 25248500
  21. Wang, X.; Luo, D.; Wu, S. Molecular dysfunctions of mitochondria-associated endoplasmic reticulum contacts in atherosclerosis. Oxid. Med. Cell. Longev., 2021, 2021, 1-8. doi: 10.1155/2021/2424509 PMID: 34336087
  22. Yassin, L.M.; Londoño, J.; Montoya, G.; De Sanctis, J.B.; Rojas, M.; Ramírez, L.A.; García, L.F.; Vásquez, G. Atherosclerosis development in SLE patients is not determined by monocytes ability to bind/endocytose Ox-LDL. Autoimmunity, 2011, 44(3), 201-210. doi: 10.3109/08916934.2010.530626 PMID: 21231894
  23. Moore, K.J.; Koplev, S.; Fisher, E.A.; Tabas, I.; Björkegren, J.L.M.; Doran, A.C.; Kovacic, J.C. Macrophage trafficking, inflammatory resolution, and genomics in atherosclerosis. J. Am. Coll. Cardiol., 2018, 72(18), 2181-2197. doi: 10.1016/j.jacc.2018.08.2147 PMID: 30360827
  24. Raines, E.W.; Ross, R. Multiple growth factors are associated with lesions of atherosclerosis: Specificity or redundancy? BioEssays, 1996, 18(4), 271-282. doi: 10.1002/bies.950180405 PMID: 8967895
  25. Holvoet, P.; Collen, D. Thrombosis and atherosclerosis. Curr. Opin. Lipidol., 1997, 8(5), 320-328. doi: 10.1097/00041433-199710000-00012 PMID: 9335957
  26. Negre-Salvayre, A.; Guerby, P.; Gayral, S.; Laffargue, M.; Salvayre, R. Role of reactive oxygen species in atherosclerosis: Lessons from murine genetic models. Free Radic. Biol. Med., 2020, 149, 8-22. doi: 10.1016/j.freeradbiomed.2019.10.011 PMID: 31669759
  27. Prasad, K.; Mishra, M. Mechanism of hypercholesterolemia-induced atherosclerosis. Rev. Cardiovasc. Med., 2022, 23(6), 212. doi: 10.31083/j.rcm2306212
  28. Schwartz, C.J.; Valente, A.J.; Sprague, E.A.; Kelley, J.L.; Nerem, R.M. The pathogenesis of atherosclerosis: An overview. Clin. Cardiol., 1991, 14(S1), 1-16. doi: 10.1002/clc.4960141302 PMID: 2044253
  29. Mohana, T.; Navin, A.V.; Jamuna, S.; Sakeena Sadullah, M.S.; Niranjali Devaraj, S. Inhibition of differentiation of monocyte to macrophages in atherosclerosis by oligomeric proanthocyanidins –In vivo and in vitro study. Food Chem. Toxicol., 2015, 82, 96-105. doi: 10.1016/j.fct.2015.04.028 PMID: 25981678
  30. Black, D.M. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr. Atheroscler. Rep., 2002, 4(1), 34-41. doi: 10.1007/s11883-002-0060-0 PMID: 11772420
  31. Stancu, C.; Sima, A. Statins: Mechanism of action and effects. J. Cell. Mol. Med., 2001, 5(4), 378-387. doi: 10.1111/j.1582-4934.2001.tb00172.x PMID: 12067471
  32. Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; Braun, L.T.; de Ferranti, S.; Faiella-Tommasino, J.; Forman, D.E.; Goldberg, R.; Heidenreich, P.A.; Hlatky, M.A.; Jones, D.W.; Lloyd-Jones, D.; Lopez-Pajares, N.; Ndumele, C.E.; Orringer, C.E.; Peralta, C.A.; Saseen, J.J.; Smith, S.C., Jr; Sperling, L.; Virani, S.S.; Yeboah, J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol. J. Am. Coll. Cardiol., 2019, 73(24), e285-e350. doi: 10.1016/j.jacc.2018.11.003 PMID: 30423393
  33. Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M.R.; Tokgozoglu, L.; Wiklund, O.; Mueller, C.; Drexel, H.; Aboyans, V.; Corsini, A.; Doehner, W.; Farnier, M.; Gigante, B.; Kayikcioglu, M.; Krstacic, G.; Lambrinou, E.; Lewis, B.S.; Masip, J.; Moulin, P.; Petersen, S.; Petronio, A.S.; Piepoli, M.F.; Pintó, X.; Räber, L.; Ray, K.K.; Reiner, Ž.; Riesen, W.F.; Roffi, M.; Schmid, J-P.; Shlyakhto, E.; Simpson, I.A.; Stroes, E.; Sudano, I.; Tselepis, A.D.; Viigimaa, M.; Vindis, C.; Vonbank, A.; Vrablik, M.; Vrsalovic, M.; Zamorano, J.L.; Collet, J-P.; Koskinas, K.C.; Casula, M.; Badimon, L.; John Chapman, M.; De Backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M-R.; Tokgozoglu, L.; Wiklund, O.; Windecker, S.; Aboyans, V.; Baigent, C.; Collet, J-P.; Dean, V.; Delgado, V.; Fitzsimons, D.; Gale, C.P.; Grobbee, D.; Halvorsen, S.; Hindricks, G.; Iung, B.; Jüni, P.; Katus, H.A.; Landmesser, U.; Leclercq, C.; Lettino, M.; Lewis, B.S.; Merkely, B.; Mueller, C.; Petersen, S.; Petronio, A.S.; Richter, D.J.; Roffi, M.; Shlyakhto, E.; Simpson, I.A.; Sousa-Uva, M.; Touyz, R.M.; Nibouche, D.; Zelveian, P.H.; Siostrzonek, P.; Najafov, R.; van de Borne, P.; Pojskic, B.; Postadzhiyan, A.; Kypris, L.; Špinar, J.; Larsen, M.L.; Eldin, H.S.; Viigimaa, M.; Strandberg, T.E.; Ferrières, J.; Agladze, R.; Laufs, U.; Rallidis, L.; Bajnok, L.; Gudjónsson, T.; Maher, V.; Henkin, Y.; Gulizia, M.M.; Mussagaliyeva, A.; Bajraktari, G.; Kerimkulova, A.; Latkovskis, G.; Hamoui, O.; Slapikas, R.; Visser, L.; Dingli, P.; Ivanov, V.; Boskovic, A.; Nazzi, M.; Visseren, F.; Mitevska, I.; Retterstøl, K.; Jankowski, P.; Fontes-Carvalho, R.; Gaita, D.; Ezhov, M.; Foscoli, M.; Giga, V.; Pella, D.; Fras, Z.; de Isla, L.P.; Hagström, E.; Lehmann, R.; Abid, L.; Ozdogan, O.; Mitchenko, O.; Patel, R.S. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J., 2020, 41(1), 111-188. doi: 10.1093/eurheartj/ehz455 PMID: 31504418
  34. Rosenson, R.S. Existing and emerging therapies for the treatment of familial hypercholesterolemia. J. Lipid Res., 2021, 62, 100060. doi: 10.1016/j.jlr.2021.100060 PMID: 33716107
  35. Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res., 1992, 33(11), 1569-1582. doi: 10.1016/S0022-2275(20)41379-3 PMID: 1464741
  36. Reiner, Ž. Management of patients with familial hypercholesterolaemia. Nat. Rev. Cardiol., 2015, 12(10), 565-575. doi: 10.1038/nrcardio.2015.92 PMID: 26076948
  37. Goldberg, A.C.; Robinson, J.G.; Cromwell, W.C.; Ross, J.L.; Ziajka, P.E. Future issues, public policy, and public awareness of familial hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol., 2011, 5(3), S46-S51. doi: 10.1016/j.jacl.2011.04.002 PMID: 21600529
  38. Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L.E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E.H.; Keech, A.; Simes, J.; Collins, R. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet, 2010, 376(9753), 1670-1681. doi: 10.1016/S0140-6736(10)61350-5 PMID: 21067804
  39. Sjouke, B.; Kusters, D.M.; Kastelein, J.J.P.; Hovingh, G.K. Familial hypercholesterolemia: Present and future management. Curr. Cardiol. Rep., 2011, 13(6), 527-536. doi: 10.1007/s11886-011-0219-9 PMID: 21938413
  40. Avis, H.J.; Hutten, B.A.; Gagné, C.; Langslet, G.; McCrindle, B.W.; Wiegman, A.; Hsia, J.; Kastelein, J.J.P.; Stein, E.A. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J. Am. Coll. Cardiol., 2010, 55(11), 1121-1126. doi: 10.1016/j.jacc.2009.10.042 PMID: 20223367
  41. Catapano, A.L.; Graham, I.; De Backer, G.; Wiklund, O.; Chapman, M.J.; Drexel, H.; Hoes, A.W.; Jennings, C.S.; Landmesser, U.; Pedersen, T.R.; Reiner, Ž.; Riccardi, G.; Taskinen, M-R.; Tokgozoglu, L.; Verschuren, W.M.M.; Vlachopoulos, C.; Wood, D.A.; Zamorano, J.L. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Atherosclerosis, 2016, 253, 281-344. doi: 10.1016/j.atherosclerosis.2016.08.018
  42. Raal, F.J.; Hovingh, G.K.; Catapano, A.L. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis, 2018, 277, 483-492. doi: 10.1016/j.atherosclerosis.2018.06.859 PMID: 30270089
  43. Hou, R.; Goldberg, A.C. Lowering low-density lipoprotein cholesterol: Statins, ezetimibe, bile acid sequestrants, and combinations: Comparative efficacy and safety. Endocrinol. Metab. Clin. North Am., 2009, 38(1), 79-97. doi: 10.1016/j.ecl.2008.11.007 PMID: 19217513
  44. Kayikcioglu, M.; Tokgozoglu, L.; Tuncel, O.K.; Pirildar, S.; Can, L. Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia. J. Clin. Lipidol., 2020, 14(6), 751-755. doi: 10.1016/j.jacl.2020.09.002 PMID: 32988799
  45. Scicali, R.; Di Pino, A.; Piro, S.; Rabuazzo, A.M.; Purrello, F. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects? Nutr. Metab. Cardiovasc. Dis., 2020, 30(7), 1068-1069. doi: 10.1016/j.numecd.2020.05.003 PMID: 32405159
  46. Frías Vargas, M.; Díaz Rodríguez, A.; Díaz Fernández, B. Lipid treatment in the period COVID-19. Semergen, 2020, 46(7), 497-502. doi: 10.1016/j.semerg.2020.06.014
  47. Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov., 2003, 2(7), 517-526. doi: 10.1038/nrd1112 PMID: 12815379
  48. Suzuki, M.; Iwasaki, H.; Fujikawa, Y.; Kitahara, M.; Sakashita, M.; Sakoda, R. Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem., 2001, 9(10), 2727-2743. doi: 10.1016/S0968-0896(01)00198-5 PMID: 11557359
  49. Bratton, L.D.; Auerbach, B.; Choi, C.; Dillon, L.; Hanselman, J.C.; Larsen, S.D.; Lu, G.; Olsen, K.; Pfefferkorn, J.A.; Robertson, A.; Sekerke, C.; Trivedi, B.K.; Unangst, P.C. Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase. Bioorg. Med. Chem., 2007, 15(16), 5576-5589. doi: 10.1016/j.bmc.2007.05.031 PMID: 17560788
  50. Larsen, S.D.; Poel, T.J.; Filipski, K.J.; Kohrt, J.T.; Pfefferkorn, J.A.; Sorenson, R.J.; Tait, B.D.; Askew, V.; Dillon, L.; Hanselman, J.C.; Lu, G.H.; Robertson, A.; Sekerke, C.; Kowala, M.C.; Auerbach, B.J. Pyrazole inhibitors of HMG-CoA reductase: An attempt to dramatically reduce synthetic complexity through minimal analog re-design. Bioorg. Med. Chem. Lett., 2007, 17(20), 5567-5572. doi: 10.1016/j.bmcl.2007.08.004 PMID: 17764936
  51. Suzuki, M.; Iwasaki, H.; Fujikawa, Y.; Sakashita, M.; Kitahara, M.; Sakoda, R. Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett., 2001, 11(10), 1285-1288. doi: 10.1016/S0960-894X(01)00203-7 PMID: 11392538
  52. Jahng, Y. Design of a new class of HMG-CoA reductase inhibitor. Drugs Future, 1995, 20(4), 387-404.
  53. Suchy, D.; Łabuzek, K.; Stadnicki, A.; Okopień, B. Ezetimibe – a new approach in hypercholesterolemia management. Pharmacol. Rep., 2011, 63(6), 1335-1348. doi: 10.1016/S1734-1140(11)70698-3 PMID: 22358082
  54. Hamilton-Craig, I.; Kostner, K.; Colquhoun, D.; Woodhouse, S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc. Health Risk Manag., 2010, 6, 1023-1037. doi: 10.2147/VHRM.S13496 PMID: 21127699
  55. Sweeney, M.E.; Johnson, R.R. Ezetimibe: An update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin. Drug Metab. Toxicol., 2007, 3(3), 441-450. doi: 10.1517/17425255.3.3.441 PMID: 17539750
  56. Nutescu, E.A.; Shapiro, N.L. Ezetimibe: A selective cholesterol absorption inhibitor. Pharmacotherapy, 2003, 23(11), 1463-1474. doi: 10.1592/phco.23.14.1463.31942 PMID: 14620392
  57. Foody, J.M.; Toth, P.P.; Tershakovec, A.M.; Musliner, T.; Tomassini, J.E.; Lowe, R.S.; Neff, D.R.; Davis, H.R. Efficacy and safety of ezetimibe plus atorvastatin therapy. Clin. Lipidol., 2014, 9(4), 441-470. doi: 10.2217/clp.14.36
  58. Clauss, S.; Wai, K.M.; Kavey, R.E.W.; Kuehl, K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J. Pediatr., 2009, 154(6), 869-872. doi: 10.1016/j.jpeds.2008.12.044 PMID: 19230898
  59. Robinson, J.G. Management of familial hypercholesterolemia: A review of the recommendations from the national lipid association expert panel on familial hypercholesterolemia. J. Manag. Care Pharm., 2013, 19(2), 139-149. doi: 10.18553/jmcp.2013.19.2.139 PMID: 23461430
  60. Liao, J.; Wang, X.; Li, Z.; Ouyang, D. Pharmacokinetic study of oral 14C-radiolabeled hyzetimibe, a new cholesterol absorption inhibitor. Front. Pharmacol., 2021, 12, 665372. doi: 10.3389/fphar.2021.665372 PMID: 34122085
  61. Ruan, Z.; jiang, B.; Chen, J.; Zhang, X.; Lou, H.; Xiang, M.; Shao, Q.; Wang, J. Pharmacokinetics, pharmacodynamics, safety, and tolerability of hyzetimibe (HS-25) in healthy Chinese subjects. J. Clin. Pharmacol., 2014, 54(10), 1144-1152. doi: 10.1002/jcph.310 PMID: 24752831
  62. Wang, Y.; Zhang, H.; Huang, W.; Kong, J.; Zhou, J.; Zhang, B. 2-Azetidinone derivatives: Design, synthesis and evaluation of cholesterol absorption inhibitors. Eur. J. Med. Chem., 2009, 44(4), 1638-1643. doi: 10.1016/j.ejmech.2008.09.033 PMID: 18990470
  63. Insull, W., Jr; Toth, P.; Mullican, W.; Hunninghake, D.; Burke, S.; Donovan, J.M.; Davidson, M.H. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial. Mayo Clin. Proc., 2001, 76(10), 971-982. doi: 10.4065/76.10.971 PMID: 11605698
  64. Shepherd, J.; Packard, C.J.; Bicker, S.; Lawrie, T.D.V.; Morgan, H.G. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N. Engl. J. Med., 1980, 302(22), 1219-1222. doi: 10.1056/NEJM198005293022202 PMID: 7366673
  65. Stein, E.A.; Marais, A.D.; Szamosi, T.; Raal, F.J.; Schurr, D.; Urbina, E.M.; Hopkins, P.N.; Karki, S.; Xu, J.; Misir, S.; Melino, M. Colesevelam hydrochloride: Efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J. Pediatr., 2010, 156(2), 231-236. doi: 10.1016/j.jpeds.2009.08.037
  66. Robinson, D.M.; Keating, G.M. Colesevelam. Am. J. Cardiovasc. Drugs, 2007, 7(6), 453-465. doi: 10.2165/00129784-200707060-00009 PMID: 18076213
  67. Tawara, K.; Tomikawa, M.; Abiko, Y. Mode of action of probucol in reducing serum cholesterol in mice. Jpn. J. Pharmacol., 1986, 40(1), 123-133. doi: 10.1254/jjp.40.123 PMID: 3959347
  68. Lau, A.K.; Leichtweis, S.B.; Hume, P.; Mashima, R.; Hou, J.Y.; Chaufour, X.; Wilkinson, B.; Hunt, N.H.; Celermajer, D.S.; Stocker, R. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation, 2003, 107(15), 2031-2036. doi: 10.1161/01.CIR.0000062682.40051.43 PMID: 12681995
  69. Buckley, M.M.T.; Goa, K.L.; Price, A.H.; Brogden, R.N. Probucol. Drugs, 1989, 37(6), 761-800. doi: 10.2165/00003495-198937060-00002 PMID: 2667936
  70. Yamashita, S.; Masuda, D.; Matsuzawa, Y. Did we abandon probucol too soon? Curr. Opin. Lipidol., 2015, 26(4), 304-316. doi: 10.1097/MOL.0000000000000199 PMID: 26125504
  71. Yamashita, S.; Bujo, H.; Arai, H.; Harada-Shiba, M.; Matsui, S.; Fukushima, M.; Saito, Y.; Kita, T.; Matsuzawa, Y. Long-term probucol treatment prevents secondary cardiovascular events: A cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J. Atheroscler. Thromb., 2008, 15(6), 292-303. doi: 10.5551/jat.E610 PMID: 19060422
  72. Ogura, M. PCSK9 inhibition in the management of familial hypercholesterolemia. J. Cardiol., 2018, 71(1), 1-7. doi: 10.1016/j.jjcc.2017.07.002 PMID: 28784313
  73. Seidah, N.G. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr. Pharm. Des., 2013, 19(17), 3161-3172. doi: 10.2174/13816128113199990313 PMID: 23317404
  74. Stein, E.A.; Honarpour, N.; Wasserman, S.M.; Xu, F.; Scott, R.; Raal, F.J. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation, 2013, 128(19), 2113-2120. doi: 10.1161/CIRCULATIONAHA.113.004678 PMID: 24014831
  75. Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; Braun, L.T.; de Ferranti, S.; Faiella-Tommasino, J.; Forman, D.E.; Goldberg, R.; Heidenreich, P.A.; Hlatky, M.A.; Jones, D.W.; Lloyd-Jones, D.; Lopez-Pajares, N.; Ndumele, C.E.; Orringer, C.E.; Peralta, C.A.; Saseen, J.J.; Smith, S.C., Jr; Sperling, L.; Virani, S.S.; Yeboah, J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139(25), e1082-e1143. doi: 10.1161/CIR.0000000000000625 PMID: 30586774
  76. Wang, Y.; Liu, Z.P. PCSK9 inhibitors: Novel therapeutic strategies for lowering LDL cholesterol. Mini Rev. Med. Chem., 2018, 19(2), 165-176. doi: 10.2174/1389557518666180423111442 PMID: 29692249
  77. Robinson, J.G.; Farnier, M.; Krempf, M.; Bergeron, J.; Luc, G.; Averna, M.; Stroes, E.S.; Langslet, G.; Raal, F.J.; El Shahawy, M.; Koren, M.J.; Lepor, N.E.; Lorenzato, C.; Pordy, R.; Chaudhari, U.; Kastelein, J.J.P. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med., 2015, 372(16), 1489-1499. doi: 10.1056/NEJMoa1501031 PMID: 25773378
  78. Sabatine, M.S.; Giugliano, R.P.; Keech, A.C.; Honarpour, N.; Wiviott, S.D.; Murphy, S.A.; Kuder, J.F.; Wang, H.; Liu, T.; Wasserman, S.M.; Sever, P.S.; Pedersen, T.R. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med., 2017, 376(18), 1713-1722. doi: 10.1056/NEJMoa1615664 PMID: 28304224
  79. McKenney, J.M. Understanding PCSK9 and anti-PCSK9 therapies. J. Clin. Lipidol., 2015, 9(2), 170-186. doi: 10.1016/j.jacl.2015.01.001 PMID: 25911073
  80. Wilkinson, M.J.; Davidson, M.H. Recent developments in the treatment of familial hypercholesterolemia: A review of several new drug classes. Curr. Treat. Options Cardiovasc. Med., 2013, 15(6), 696-705. doi: 10.1007/s11936-013-0272-3 PMID: 24222265
  81. Ling, H.; Burns, T.L.; Hilleman, D.E. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Cardiovasc. Ther., 2014, 32(2), 82-88. doi: 10.1111/1755-5922.12056 PMID: 24354905
  82. Torres, E.; Goicoechea, M.; Hernández, A.; Rodríguez Ferrero, M.L.; García, A.; Macías, N.; Anaya, F. Efficacy of Evolocumab vs. low density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01). J. Clin. Apher., 2020, 35(1), 9-17. doi: 10.1002/jca.21752 PMID: 31663632
  83. Di Minno, M.N.D.; Gentile, M.; Di Minno, A.; Iannuzzo, G.; Calcaterra, I.; Buonaiuto, A.; Di Taranto, M.D.; Giacobbe, C.; Fortunato, G.; Rubba, P.O.F. Changes in carotid stiffness in patients with familial hypercholesterolemia treated with Evolocumab®: A prospective cohort study. Nutr. Metab. Cardiovasc. Dis., 2020, 30(6), 996-1004. doi: 10.1016/j.numecd.2020.02.018 PMID: 32402582
  84. Mahmood, T.; Minnier, J.; Ito, M.K.; Li, Q.H.; Koren, A.; Kam, I.W.; Fazio, S.; Shapiro, M.D. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur. J. Prev. Cardiol., 2021, 28(8), 816-822. doi: 10.1177/2047487320915803 PMID: 34298554
  85. Yadav, K.; Sharma, M.; Ferdinand, K.C. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Nutr. Metab. Cardiovasc. Dis., 2016, 26(10), 853-862. doi: 10.1016/j.numecd.2016.05.006 PMID: 27352986
  86. Rosenson, R.S.; Hegele, R.A.; Fazio, S.; Cannon, C.P. The evolving future of PCSK9 inhibitors. J. Am. Coll. Cardiol., 2018, 72(3), 314-329. doi: 10.1016/j.jacc.2018.04.054 PMID: 30012326
  87. Fitzgerald, K.; White, S.; Borodovsky, A.; Bettencourt, B.R.; Strahs, A.; Clausen, V.; Wijngaard, P.; Horton, J.D.; Taubel, J.; Brooks, A.; Fernando, C.; Kauffman, R.S.; Kallend, D.; Vaishnaw, A.; Simon, A. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med., 2017, 376(1), 41-51. doi: 10.1056/NEJMoa1609243 PMID: 27959715
  88. Ray, K.K.; Landmesser, U.; Leiter, L.A.; Kallend, D.; Dufour, R.; Karakas, M.; Hall, T.; Troquay, R.P.T.; Turner, T.; Visseren, F.L.J.; Wijngaard, P.; Wright, R.S.; Kastelein, J.J.P. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med., 2017, 376(15), 1430-1440. doi: 10.1056/NEJMoa1615758 PMID: 28306389
  89. Gennemark, P.; Walter, K.; Clemmensen, N.; Rekić, D.; Nilsson, C.A.M.; Knöchel, J.; Hölttä, M.; Wernevik, L.; Rosengren, B.; Kakol-Palm, D.; Wang, Y.; Yu, R.Z.; Geary, R.S.; Riney, S.J.; Monia, B.P.; Isaksson, R.; Jansson-Löfmark, R.; Rocha, C.S.J.; Lindén, D.; Hurt-Camejo, E.; Crooke, R.; Tillman, L.; Rydén-Bergsten, T.; Carlsson, B.; Andersson, U.; Elebring, M.; Tivesten, A.; Davies, N. An oral antisense oligonucleotide for PCSK9 inhibition. Sci. Transl. Med., 2021, 13(593), eabe9117. doi: 10.1126/scitranslmed.abe9117 PMID: 33980578
  90. Zhang, Y.; Eigenbrot, C.; Zhou, L.; Shia, S.; Li, W.; Quan, C.; Tom, J.; Moran, P.; Di Lello, P.; Skelton, N.J.; Kong- Beltran, M.; Peterson, A.; Kirchhofer, D. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J. Biol. Chem., 2014, 289(2), 942-955. doi: 10.1074/jbc.M113.514067 PMID: 24225950
  91. Zhang, Y.; Ultsch, M.; Skelton, N.J.; Burdick, D.J.; Beresini, M.H.; Li, W.; Kong-Beltran, M.; Peterson, A.; Quinn, J.; Chiu, C.; Wu, Y.; Shia, S.; Moran, P.; Di Lello, P.; Eigenbrot, C.; Kirchhofer, D. Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. Nat. Struct. Mol. Biol., 2017, 24(10), 848-856. doi: 10.1038/nsmb.3453 PMID: 28825733
  92. Lintner, N.G.; McClure, K.F.; Petersen, D.; Londregan, A.T.; Piotrowski, D.W.; Wei, L.; Xiao, J.; Bolt, M.; Loria, P.M.; Maguire, B.; Geoghegan, K.F.; Huang, A.; Rolph, T.; Liras, S.; Doudna, J.A.; Dullea, R.G.; Cate, J.H.D. Selective stalling of human translation through small- molecule engagement of the ribosome nascent chain. PLoS Biol., 2017, 15(3), e2001882. doi: 10.1371/journal.pbio.2001882 PMID: 28323820
  93. Liu, J.W.; Jiang, B.; Zhao, S.P.; Cai, S.Y.; Huang, M.H.; Fang, P.F.; Ruan, Z.R.; Chen, M.L.; Shou, Q.Y.; Briand, F.; Wang, J.A. CVI-LM001, a first-in-class novel oral PCSK9 modulator for hypercholesterolemia and NASH: Preclinical and first-in-human studies. Hepatology, 2020, 72(1)(Suppl.), 1014.
  94. Cao, S.; Xu, P.; Yan, J.; Liu, H.; Liu, L.; Cheng, L.; Qiu, F.; Kang, N. Berberrubine and its analog, hydroxypropyl berberrubine, regulate LDL-R and PCSK9 expression via the ERK signal pathway to exert cholesterol lowering effects in human hepatoma HepG2 cells. J. Cell. Biochem., 2019, 120(2), 1340-1349. doi: 10.1002/jcb.27102 PMID: 30335889
  95. Jia, Y.J.; Xu, R.X.; Sun, J.; Tang, Y.; Li, J.J. Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats. J. Transl. Med., 2014, 12(1), 103. doi: 10.1186/1479-5876-12-103 PMID: 24755036
  96. Tai, M.H.; Chen, P.K.; Chen, P.Y.; Wu, M.J.; Ho, C.T.; Yen, J.H. Curcumin enhances cell-surface LDL-R level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Mol. Nutr. Food Res., 2014, 58(11), 2133-2145. doi: 10.1002/mnfr.201400366 PMID: 25164566
  97. Rader, D.J.; Kastelein, J.J.P. Lomitapide and mipomersen. Circulation, 2014, 129(9), 1022-1032. doi: 10.1161/CIRCULATIONAHA.113.001292 PMID: 24589695
  98. Davis, K.A.; Miyares, M.A. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Am. J. Health Syst. Pharm., 2014, 71(12), 1001-1008. doi: 10.2146/ajhp130592 PMID: 24865757
  99. Cuchel, M.; Meagher, E.A.; du Toit Theron, H.; Blom, D.J.; Marais, A.D.; Hegele, R.A.; Averna, M.R.; Sirtori, C.R.; Shah, P.K.; Gaudet, D.; Stefanutti, C.; Vigna, G.B.; Du Plessis, A.M.E.; Propert, K.J.; Sasiela, W.J.; Bloedon, L.T.; Rader, D.J. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet, 2013, 381(9860), 40-46. doi: 10.1016/S0140-6736(12)61731-0 PMID: 23122768
  100. Berberich, A.J.; Hegele, R.A. Lomitapide for the treatment of hypercholesterolemia. Expert Opin. Pharmacother., 2017, 18(12), 1261-1268. doi: 10.1080/14656566.2017.1340941 PMID: 28598687
  101. Cuchel, M.; Bloedon, L.T.; Szapary, P.O.; Kolansky, D.M.; Wolfe, M.L.; Sarkis, A.; Millar, J.S.; Ikewaki, K.; Siegelman, E.S.; Gregg, R.E.; Rader, D.J. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med., 2007, 356(2), 148-156. doi: 10.1056/NEJMoa061189 PMID: 17215532
  102. Averna, M.; Cefalù, A.B.; Stefanutti, C.; Di Giacomo, S.; Sirtori, C.R.; Vigna, G. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. Nutr. Metab. Cardiovasc. Dis., 2016, 26(1), 36-44. doi: 10.1016/j.numecd.2015.11.001 PMID: 26723464
  103. Tuteja, S.; Duffy, D.; Dunbar, R.L.; Movva, R.; Gadi, R.; Bloedon, L.T.; Cuchel, M. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia. Pharmacotherapy, 2014, 34(3), 227-239. doi: 10.1002/phar.1351 PMID: 24734312
  104. Markham, A. Evinacumab: First approval. Drugs, 2021, 81(9), 1101-1105. doi: 10.1007/s40265-021-01516-y PMID: 34003472
  105. Ling, P.; Zheng, X.; Luo, S.; Ge, J.; Xu, S.; Weng, J. Targeting angiopoietin like 3 in atherosclerosis: From bench to bedside. Diabetes Obes. Metab., 2021, 23(9), 2020-2034. doi: 10.1111/dom.14450 PMID: 34047441
  106. Christopoulou, E.; Elisaf, M.; Filippatos, T. Effects of angiopoietin-like 3 on triglyceride regulation, glucose homeostasis, and diabetes. Dis. Markers, 2019, 2019, 1-8. doi: 10.1155/2019/6578327 PMID: 30944669
  107. Lu, X. Structure and function of angiopoietin-like protein 3 (ANGPTL3) in atherosclerosis. Curr. Med. Chem., 2020, 27(31), 5159-5174. doi: 10.2174/0929867326666190621120523 PMID: 31223079
  108. Lang, W.; Frishman, W.H. Angiopoietin-like 3 protein inhibition: A new frontier in lipid-lowering treatment. Cardiol. Rev., 2019, 27(4), 211-217. doi: 10.1097/CRD.0000000000000258 PMID: 31008773
  109. Mohamed, F.; Botha, T.C.; Raal, F.J. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr. Opin. Lipidol., 2021, 32(4), 213-218. doi: 10.1097/MOL.0000000000000755 PMID: 33883446
  110. Wang, Y.; Gusarova, V.; Banfi, S.; Gromada, J.; Cohen, J.C.; Hobbs, H.H. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J. Lipid Res., 2015, 56(7), 1296-1307. doi: 10.1194/jlr.M054882 PMID: 25954050
  111. Dewey, F.E.; Gusarova, V.; Dunbar, R.L.; O’Dushlaine, C.; Schurmann, C.; Gottesman, O.; McCarthy, S.; Van Hout, C.V.; Bruse, S.; Dansky, H.M.; Leader, J.B.; Murray, M.F.; Ritchie, M.D.; Kirchner, H.L.; Habegger, L.; Lopez, A.; Penn, J.; Zhao, A.; Shao, W.; Stahl, N.; Murphy, A.J.; Hamon, S.; Bouzelmat, A.; Zhang, R.; Shumel, B.; Pordy, R.; Gipe, D.; Herman, G.A.; Sheu, W.H.H.; Lee, I.T.; Liang, K.W.; Guo, X.; Rotter, J.I.; Chen, Y.D.I.; Kraus, W.E.; Shah, S.H.; Damrauer, S.; Small, A.; Rader, D.J.; Wulff, A.B.; Nordestgaard, B.G.; Tybjærg-Hansen, A.; van den Hoek, A.M.; Princen, H.M.G.; Ledbetter, D.H.; Carey, D.J.; Overton, J.D.; Reid, J.G.; Sasiela, W.J.; Banerjee, P.; Shuldiner, A.R.; Borecki, I.B.; Teslovich, T.M.; Yancopoulos, G.D.; Mellis, S.J.; Gromada, J.; Baras, A. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N. Engl. J. Med., 2017, 377(3), 211-221. doi: 10.1056/NEJMoa1612790 PMID: 28538136
  112. Mohamed, F.; Seedat, F.; Raal, F.J. Novel therapies for familial hypercholesterolemia. Curr. Opin. Endocrinol. Diabetes Obes., 2021, 28(2), 188-195. doi: 10.1097/MED.0000000000000590 PMID: 33278127
  113. Warden, B.A.; Duell, P.B. Evinacumab for treatment of familial hypercholesterolemia. Expert Rev. Cardiovasc. Ther., 2021, 19(8), 739-751. doi: 10.1080/14779072.2021.1955349 PMID: 34253139
  114. Brandts, J.; Ray, K.K. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: Early indications and potential. Expert Opin. Investig. Drugs, 2020, 29(8), 763-770. doi: 10.1080/13543784.2020.1778668 PMID: 32564642
  115. Ballantyne, C.M.; Bays, H.; Catapano, A.L.; Goldberg, A.; Ray, K.K.; Saseen, J.J. Role of bempedoic acid in clinical practice. Cardiovasc. Drugs Ther., 2021, 35(4), 853-864. doi: 10.1007/s10557-021-07147-5 PMID: 33818688
  116. Kelly, M.S.; Sulaica, E.M.; Beavers, C.J. Role of bempedoic acid in dyslipidemia management. J. Cardiovasc. Pharmacol., 2020, 76(4), 376-388. doi: 10.1097/FJC.0000000000000887 PMID: 32732494
  117. Susekov, A.V.; Korol, L.A.; Watts, G.F. Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance. Cardiovasc. Drugs Ther., 2021, 35(4), 841-852. doi: 10.1007/s10557-020-07139-x PMID: 33502687
  118. Marrs, J.C.; Anderson, S.L. Bempedoic acid for the treatment of dyslipidemia. Drugs Context, 2020, 9(9), 1-9. doi: 10.7573/dic.2020-6-5 PMID: 32922503
  119. Broekhuizen, K.; Jelsma GM, J.; van PoppelNM, M.; Koppes LJ, L.; Brug, J.; van Mechelen, W. Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviours in people with Familial Hypercholesterolemia? BMC Public Health, 2012, 12(1), 348. doi: 10.1186/1471-2458-12-348 PMID: 22583789
  120. McGuire, S. Scientific Report of the 2015 Dietary Guidelines Advisory Committee. Washington, DC: US Departments of Agriculture and Health and Human Services, 2015. Adv. Nutr., 2016, 7(1), 202-204. doi: 10.3945/an.115.011684 PMID: 26773024
  121. Smith, S.C., Jr; Allen, J.; Blair, S.N.; Bonow, R.O.; Brass, L.M.; Fonarow, G.C.; Grundy, S.M.; Hiratzka, L.; Jones, D.; Krumholz, H.M.; Mosca, L.; Pasternak, R.C.; Pearson, T.; Pfeffer, M.A.; Taubert, K.A. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation, 2006, 113(19), 2363-2372. doi: 10.1161/CIRCULATIONAHA.106.174516 PMID: 16702489
  122. Moruisi, K.G.; Oosthuizen, W.; Opperman, A.M. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: A systematic review with meta-analysis. J. Am. Coll. Nutr., 2006, 25(1), 41-48. doi: 10.1080/07315724.2006.10719513 PMID: 16522931
  123. Jansen, A.C.M.; Aalst-Cohen, E.S.; Tanck, M.W.; Trip, M.D.; Lansberg, P.J.; Liem, A.H.; Roeters van Lennep, H.W.O.; Sijbrands, E.J.G.; Kastelein, J.J.P. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: Data in 2400 patients. J. Intern. Med., 2004, 256(6), 482-490. doi: 10.1111/j.1365-2796.2004.01405.x PMID: 15554949
  124. Alonso, R.; Mata, N.; Castillo, S.; Fuentes, F.; Saenz, P.; Muñiz, O.; Galiana, J.; Figueras, R.; Diaz, J.L.; Gomez-Enterría, P.; Mauri, M.; Piedecausa, M.; Irigoyen, L.; Aguado, R.; Mata, P. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis, 2008, 200(2), 315-321. doi: 10.1016/j.atherosclerosis.2007.12.024 PMID: 18243212
  125. Page, M.M.; Bell, D.A.; Hooper, A.J.; Watts, G.F.; Burnett, J.R. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Pract. Res. Clin. Endocrinol. Metab., 2014, 28(3), 387-403. doi: 10.1016/j.beem.2013.10.004 PMID: 24840266
  126. Thompson, G.R. Recommendations for the use of LDL apheresis. Atherosclerosis, 2008, 198(2), 247-255. doi: 10.1016/j.atherosclerosis.2008.02.009 PMID: 18371971
  127. Moriarty, P.M.; Hemphill, L. Lipoprotein apheresis. Cardiol. Clin., 2015, 33(2), 197-208. doi: 10.1016/j.ccl.2015.02.002 PMID: 25939293
  128. Stefanutti, C.; Thompson, G.R. Lipoprotein apheresis in the management of familial hypercholesterolaemia: Historical perspective and recent advances. Curr. Atheroscler. Rep., 2015, 17(1), 465. doi: 10.1007/s11883-014-0465-6 PMID: 25410046
  129. Makino, H.; Koezuka, R.; Tamanaha, T.; Ogura, M.; Matsuki, K.; Hosoda, K.; Harada-Shiba, M. Familial hypercholesterolemia and lipoprotein apheresis. J. Atheroscler. Thromb., 2019, 26(8), 679-687. doi: 10.5551/jat.RV17033 PMID: 31231083
  130. Stefanutti, C.; Julius, U.; Watts, G.F.; Harada-Shiba, M.; Cossu, M.; Schettler, V.J.; De Silvestro, G.; Soran, H.; Van Lennep, J.R.; Pisciotta, L.; Klör, H.U.; Widhalm, K.; Moriarty, P.M.; D’Alessandri, G.; Bianciardi, G.; Bosco, G.; De Fusco, G.; Di Giacomo, S.; Morozzi, C.; Mesce, D.; Vitale, M.; Sovrano, B.; Drogari, E.; Ewald, N.; Gualdi, G.; Jaeger, B.R.; Lanti, A.; Marson, P.; Martino, F.; Migliori, G.; Parasassi, T.; Pavan, A.; Perla, F.M.; Brunelli, R.; Perrone, G.; Renga, S.; Ries, W.; Romano, N.; Romeo, S.; Pergolini, M.; Labbadia, G.; Di Iorio, B.; De Palo, T.; Abbate, R.; Marcucci, R.; Poli, L.; Ardissino, G.; Ottone, P.; Tison, T.; Favari, E.; Borgese, L.; Shafii, M.; Gozzer, M.; Pacella, E.; Torromeo, C.; Parassassi, T.; Berni, A.; Guardamagna, O.; Zenti, M.G.; Guitarrini, M.R.; Berretti, D.; Hohenstein, B.; Saheb, S.; Bjelakovic, B.; Williams, H. Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs. J. Clin. Lipidol., 2017, 11(4), 858-871. doi: 10.1016/j.jacl.2017.04.114 PMID: 28572002
  131. Wang, A.; Richhariya, A.; Gandra, S.R.; Calimlim, B.; Kim, L.; Quek, R.G.W.; Nordyke, R.J.; Toth, P.P. Systematic review of low density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J. Am. Heart Assoc., 2016, 5(7), e003294. doi: 10.1161/JAHA.116.003294 PMID: 27385428
  132. Thompson, G.; Parhofer, K.G. Current role of lipoprotein apheresis. Curr. Atheroscler. Rep., 2019, 21(7), 26. doi: 10.1007/s11883-019-0787-5 PMID: 31041550
  133. Koziolek, M.J.; Mueller, G.A. Impact of LDL-Apheresis on inflammation and microcirculation. Atheroscler. Suppl., 2009, 10(5), 56-58. doi: 10.1016/S1567-5688(09)71812-4 PMID: 20129376
  134. Stefanutti, C.; Morozzi, C.; Petta, A. Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine, 2011, 56(3), 842-849. doi: 10.1016/j.cyto.2011.08.027 PMID: 21920771
  135. France, M.; Rees, A.; Datta, D.; Thompson, G.; Capps, N.; Ferns, G.; Ramaswami, U.; Seed, M.; Neely, D.; Cramb, R.; Shoulders, C.; Barbir, M.; Pottle, A.; Eatough, R.; Martin, S.; Bayly, G.; Simpson, B.; Halcox, J.; Edwards, R.; Main, L.; Payne, J.; Soran, H. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis, 2016, 255, 128-139. doi: 10.1016/j.atherosclerosis.2016.10.017 PMID: 27839699
  136. Kayikcioglu, M.; Tokgozoglu, L.; Yilmaz, M.; Kaynar, L.; Aktan, M.; Durmuş, R.B.; Gokce, C.; Temizhan, A.; Ozcebe, O.I.; Akyol, T.K.; Okutan, H.; Sag, S.; Gul, O.O.; Salcioglu, Z.; Yenercag, M.; Altunkeser, B.B.; Kuku, I.; Yasar, H.Y.; Kurtoglu, E.; Kose, M.D.; Demircioglu, S.; Pekkolay, Z.; Ilhan, O. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). Atherosclerosis, 2018, 270, 42-48. doi: 10.1016/j.atherosclerosis.2018.01.034 PMID: 29407887
  137. Cuchel, M.; Bruckert, E.; Ginsberg, H.N.; Raal, F.J.; Santos, R.D.; Hegele, R.A.; Kuivenhoven, J.A.; Nordestgaard, B.G.; Descamps, O.S.; Steinhagen-Thiessen, E.; Tybjaerg-Hansen, A.; Watts, G.F.; Averna, M.; Boileau, C.; Borén, J.; Catapano, A.L.; Defesche, J.C.; Hovingh, G.K.; Humphries, S.E.; Kovanen, P.T.; Masana, L.; Pajukanta, P.; Parhofer, K.G.; Ray, K.K.; Stalenhoef, A.F.H.; Stroes, E.; Taskinen, M.R.; Wiegman, A.; Wiklund, O.; Chapman, M.J.; Cuchel, M.; Bruckert, E.; Chapman, M.J.; Descamps, O.S.; Ginsberg, H.N.; Hegele, R.A.; Kuivenhoven, J.A.; Nordestgaard, B.G.; Raal, F.J.; Santos, R.D.; Steinhagen-Thiessen, E.; Tybjaerg-Hansen, A.; Watts, G.F.; Chapman, M.J.; Ginsberg, H.N.; Averna, M.; Boileau, C.; Boren, J.; Catapano, A.L.; Defesche, J.C.; Hovingh, G.K.; Humphries, S.E.; Kovanen, P.T.; Masana, L.; Pajukanta, P.; Parhofer, K.G.; Ray, K.K.; Stalenhoef, A.F.H.; Stroes, E.; Taskinen, M-R.; Wiegman, A.; Wiklund, O. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J., 2014, 35(32), 2146-2157. doi: 10.1093/eurheartj/ehu274 PMID: 25053660
  138. Kayıkçıoğlu, M.; Kısmalı, E.; Can, L.; Payzin, S. Long-term follow-up in patients with homozygous familial hypercholesterolemia; 13-year experience of a university hospital lipid clinic. Turk Kardiyol Dern Ars, 2014, 42(7), 599-611. doi: 10.5543/tkda.2014.09633
  139. Padmanabhan, A.; Connelly-Smith, L.; Aqui, N.; Balogun, R.A.; Klingel, R.; Meyer, E.; Pham, H.P.; Schneiderman, J.; Witt, V.; Wu, Y.; Zantek, N.D.; Dunbar, N.M.; Schwartz, G.E.J. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence Based Approach from the Writing Committee of the American Society for Apheresis: The eighth special issue. J. Clin. Apher., 2019, 34(3), 171-354. doi: 10.1002/jca.21705 PMID: 31180581
  140. Thompson, G.R. Managing homozygous familial hypercholesterolaemia from cradle to grave. Atheroscler. Suppl., 2015, 18, 16-20. doi: 10.1016/j.atherosclerosissup.2015.02.002 PMID: 25936299
  141. Harada-Shiba, M.; Arai, H.; Oikawa, S.; Ohta, T.; Okada, T.; Okamura, T.; Nohara, A.; Bujo, H.; Yokote, K.; Wakatsuki, A.; Ishibashi, S.; Yamashita, S. Guidelines for the management of familial hypercholesterolemia. J. Atheroscler. Thromb., 2012, 19(12), 1043-1060. doi: 10.5551/jat.14621 PMID: 23095242
  142. Goldberg, A.C.; Hopkins, P.N.; Toth, P.P.; Ballantyne, C.M.; Rader, D.J.; Robinson, J.G.; Daniels, S.R.; Gidding, S.S.; de Ferranti, S.D.; Ito, M.K.; McGowan, M.P.; Moriarty, P.M.; Cromwell, W.C.; Ross, J.L.; Ziajka, P.E. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. J. Clin. Lipidol., 2011, 5(3), S1-S8. doi: 10.1016/j.jacl.2011.04.003 PMID: 21600525
  143. Stefanutti, C.; Julius, U. Lipoprotein apheresis: State of the art and novelties. Atheroscler. Suppl., 2013, 14(1), 19-27. doi: 10.1016/j.atherosclerosissup.2012.10.021 PMID: 23357136
  144. Kayikcioglu, M.; Kuman-Tunçel, O.; Pirildar, S.; Yílmaz, M.; Kaynar, L.; Aktan, M.; Durmuş, R.B.; Gökçe, C.; Temizhan, A.; Özcebe, O.I.; Akyol, T.K.; Okutan, H.; Sağ, S.; Oz Gul, O.; Salcioglu, Z.; Yenercag, M.; Altunkeser, B.B.; Kuku, I.; Yasar, H.Y.; Kurtoğlu, E.; Demir, M.; Demircioğlu, S.; Pekkolay, Z.; Ílhan, O.; Tokgozoglu, L. Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry). J. Clin. Lipidol., 2019, 13(3), 455-467. doi: 10.1016/j.jacl.2019.02.001 PMID: 30928440
  145. Bilheimer, D.W.; Goldstein, J.L.; Grundy, S.M.; Starzl, T.E.; Brown, M.S. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N. Engl. J. Med., 1984, 311(26), 1658-1664. doi: 10.1056/NEJM198412273112603 PMID: 6390206
  146. Alim, A.; Tokat, Y.; Erdogan, Y.; Gokkaya, Z.; Dayangac, M.; Yuzer, Y.; Oezcelik, A. Liver transplantation for homozygote familial hypercholesterolemia: The only curative treatment. Pediatr. Transplant., 2016, 20(8), 1060-1064. doi: 10.1111/petr.12763 PMID: 27435024
  147. Page, M.M.; Ekinci, E.I.; Jones, R.M.; Angus, P.W.; Gow, P.J.; O’Brien, R.C. Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies. Intern. Med. J., 2014, 44(6), 601-604. doi: 10.1111/imj.12444 PMID: 24946816
  148. Kolovou, G.; Vasiliadis, I.; Gontoras, N.; Kolovou, V.; Hatzigeorgiou, G. Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance. Cardiovasc. Ther., 2015, 33(2), 71-78. doi: 10.1111/1755-5922.12105 PMID: 25604780
  149. Lyseng-Willliamson, K.A.; Perry, C.M. Lomitapide: A guide to its use in adults with homozygous familial hypercholesterolaemia in the EU. Drugs Ther. Perspect., 2013, 29(12), 373-378. doi: 10.1007/s40267-013-0087-z
  150. Moini, M.; Mistry, P.; Schilsky, M.L. Liver transplantation for inherited metabolic disorders of the liver. Curr. Opin. Organ Transplant., 2010, 15(3), 269-276. doi: 10.1097/MOT.0b013e3283399dbd PMID: 20489626
  151. Ibrahim, M.; El-Hamamsy, I.; Barbir, M.; Yacoub, M.H. Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively. J. Cardiovasc. Transl. Res., 2012, 5(3), 351-358. doi: 10.1007/s12265-011-9311-1 PMID: 21882079
  152. Ishigaki, Y.; Kawagishi, N.; Hasegawa, Y.; Sawada, S.; Katagiri, H.; Satomi, S.; Oikawa, S. Liver transplantation for homozygous familial hypercholesterolemia. J. Atheroscler. Thromb., 2019, 26(2), 121-127. doi: 10.5551/jat.RV17029 PMID: 30555131
  153. Malatack MD, J.J. Liver transplantation as treatment for familial homozygous hypercholesterolemia: Too early or too late. Pediatr. Transplant., 2011, 15(2), 123-125. doi: 10.1111/j.1399-3046.2010.01458.x PMID: 21219559
  154. Hackl, C.; Schlitt, H.J.; Melter, M.; Knoppke, B.; Loss, M. Current developments in pediatric liver transplantation. World J. Hepatol., 2015, 7(11), 1509-1520. doi: 10.4254/wjh.v7.i11.1509 PMID: 26085910
  155. Goldmann, R.; Tichý, L.; Freiberger, T.; Zapletalová, P.; Letocha, O.; Soška, V.; Fajkus, J.; Fajkusová, L. Genomic characterization of large rearrangements of the LDL-R gene in Czech patients with familial hypercholesterolemia. BMC Med. Genet., 2010, 11(1), 115. doi: 10.1186/1471-2350-11-115 PMID: 20663204
  156. Van Craeyveld, E.; Jacobs, F.; Gordts, S.C.; De Geest, B. Gene therapy for familial hypercholesterolemia. Curr. Pharm. Des., 2011, 17(24), 2575-2591. doi: 10.2174/138161211797247550 PMID: 21774774
  157. Soria, L.F.; Ludwig, E.H.; Clarke, H.R.; Vega, G.L.; Grundy, S.M.; McCarthy, B.J. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc. Natl. Acad. Sci. USA, 1989, 86(2), 587-591. doi: 10.1073/pnas.86.2.587 PMID: 2563166
  158. Palacios, L.; Grandoso, L.; Cuevas, N.; Olano-Martín, E.; Martinez, A.; Tejedor, D.; Stef, M. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis, 2012, 221(1), 137-142. doi: 10.1016/j.atherosclerosis.2011.12.021 PMID: 22244043
  159. Varret, M.; Abifadel, M.; Rabès, J-P.; Boileau, C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin. Genet., 2008, 73(1), 1-13. doi: 10.1111/j.1399-0004.2007.00915.x PMID: 18028451
  160. Iacocca, M.A.; Chora, J.R.; Carrié, A.; Freiberger, T.; Leigh, S.E.; Defesche, J.C.; Kurtz, C.L.; DiStefano, M.T.; Santos, R.D.; Humphries, S.E.; Mata, P.; Jannes, C.E.; Hooper, A.J.; Wilemon, K.A.; Benlian, P.; O’Connor, R.; Garcia, J.; Wand, H.; Tichy, L.; Sijbrands, E.J.; Hegele, R.A.; Bourbon, M.; Knowles, J.W. ClinVar database of global familial hypercholesterolemia associated DNA variants. Hum. Mutat., 2018, 39(11), 1631-1640. doi: 10.1002/humu.23634 PMID: 30311388
  161. Berberich, A.J.; Hegele, R.A. The complex molecular genetics of familial hypercholesterolaemia. Nat. Rev. Cardiol., 2019, 16(1), 9-20. doi: 10.1038/s41569-018-0052-6 PMID: 29973710
  162. Al-Allaf, F.A.; Coutelle, C.; Waddington, S.N.; David, A.L.; Harbottle, R.; Themis, M. LDLR-Gene therapy for familial hypercholesterolaemia: Problems, progress, and perspectives. Int. Arch. Med., 2010, 3(1), 36. doi: 10.1186/1755-7682-3-36 PMID: 21144047
  163. Van Craeyveld, E.; Gordts, S.C.; Nefyodova, E.; Jacobs, F.; De Geest, B. Regression and stabilization of advanced murine atherosclerotic lesions: A comparison of LDL lowering and HDL raising gene transfer strategies. J. Mol. Med. (Berl.), 2011, 89(6), 555-567. doi: 10.1007/s00109-011-0722-x PMID: 21249329
  164. Kassim, S.H.; Li, H.; Vandenberghe, L.H.; Hinderer, C.; Bell, P.; Marchadier, D.; Wilson, A.; Cromley, D.; Redon, V.; Yu, H.; Wilson, J.M.; Rader, D.J. Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. PLoS One, 2010, 5(10), e13424. doi: 10.1371/journal.pone.0013424 PMID: 20976059
  165. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126(4), 663-676. doi: 10.1016/j.cell.2006.07.024 PMID: 16904174

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers